Weil is advising Halozyme Therapeutics, Inc. (NASDAQ: HALO) in its definitive agreement to acquire Elektrofi, Inc., a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon™. The transaction, which is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi.

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines.

The Weil team is led by Mergers & Acquisitions partners Michael J. Aiello and Sachin Kohli and includes Mergers & Acquisitions associates Brandon Nesfield, Avi Rubin and Ryan Blom; Technology & IP Transactions partner Dennis Adams and associates Sabrina Chishti and Sarah Schwarz; IP, Technology & Science Litigation partner Gabriel Gross and associate Rashi Punia; U.S. Privacy and Cybersecurity Head Olivia Greer and associate Jeeyoon Chung; Executive Compensation & Benefits Head Paul Wessel, partner Jack Stratton and associate Emily Warren; Employment partner Peter Mee and associate Paige Mickel; Tax partner Alfonso Dulcey and associate Marvin Zanders; Real Estate Co-Head Jannelle Seales and associate Douglas Illsley; Antitrust partner John Scribner, counsel Michael Naughton and associate Meghana Appalaraju; Regulatory Transactions partners John O’Loughlin and counsel Ariel Fliman; Foreign Investment & Trade partner Timothy C. Welch; and Governance, Securities & Reporting Group Co-Head Lyuba Goltser and associate Amanda Zoda.